




# Society of Toxicologic Pathology - India (STP-I)



## Ninth Conference and Continuing Education Program on **Immuno-Oncology Therapeutics and Toxicologic Pathology of Special Sense Organs**

**27-29 October, 2023**

**Hotel Narayani Heights**  
Ahmedabad Airport-Gandhinagar Road,  
Adjacent to Apollo Hospital, Bhat,  
Gandhinagar, Gujarat- 382428, India

**Venue**  
**Hotel Narayani Heights**





## Few reasons to attend this conference

Scientific program featuring diverse range of sessions that are highly relevant to our day to day practice in industry, covering topics such as:

- Anatomy, physiology, immunology, and toxicologic pathology of tactile and gustatory sense organs in laboratory animals
- Ocular comparative anatomy in the preclinical setting
- Ocular drug development
- Safety and efficacy of Cancer Immunotherapies
- NSG mouse models in immune-oncology therapeutics
- ADCs – aspirations for the design of next generation molecules
- Immune-mediated adverse effects
- Translatable Efficacy & Safety Testing of mAb, Bispecific & CAR T Therapies in Immune Humanized Platforms
- SMAC mimetics and IL15-PD1-mediated toxicities in monkeys
- Case studies
- Peer review



# Welcome Message



Dear Colleagues,

I am delighted beyond measure to welcome all of you to the 'Ninth conference of the Society of Toxicologic Pathology - India (STPI) to deliberate on a few topics in "Immuno-oncology Therapeutics and Toxicologic Pathology of Special Sense Organs' at Ahmedabad, a vibrant world heritage and financial capital of Gujarat, India.

The ninth STPI meeting will include a wide-ranging scientific program with distinguished plenary speakers, a popular Poster Session, an Awards Ceremony, and professional networking and cultural events. As you see from the program overview, the Central Committee of the STPI invited learned speakers from India and other parts of the globe. This collegial atmosphere of the meeting is the hallmark of STPI. This October gathering brings together a community of toxicologic pathologists conducive to idea exchange, continuing education, and professional networking. This meeting is unique regarding the theme, which addresses scientific and technical challenges in the toxicologic pathology of immune-oncology therapeutics and special sense organs. It brings together leading experts from the broader scientific community, including industry, academia, and consultants.

Ocular toxicology pathology plays a vital role in nonclinical safety assessment due to the critical importance of vision for humans and its severe health and socio-economic consequences. The evaluation of ocular tissues for efficacious or toxic effects has many challenges shared with non-ocular tissues, while others are eye-specific. Accurate identification and diagnosis of microscopic findings in ocular tissues require knowledge and understanding of clinical ocular findings, which will be shared by our eminent speakers today.

The ear is often overlooked in routine nonclinical toxicity studies, both functionally and morphologically. Typically, ear lesions observed in toxicology studies are limited to the pinna and external ear canal, which are evaluated along with the integument and associated adnexal glands. However, the ear encompasses much more than just these external features. Neglecting to consider the potential for ototoxicity in the middle and inner ear due to exposure to certain drugs or environmental contaminants can have severe consequences. As otic therapies develop, there is a growing need for toxicologic evaluation of the ear. These assessments require understanding the ear's anatomy and physiology, including key species and strain differences, and the cellular targets for ototoxicants that our expert speakers will address in this meeting.

The olfactory system plays a crucial role in toxicologic pathology because it is the primary route of exposure for many airborne toxins. When inhaled, these toxins can cause pathology to the respiratory system and other organs, leading to a range of health problems. In toxicologic pathology, the pathologists focus on understanding the impact of toxic substances on the nasal cavity, olfactory bulb/nerve, nasal epithelium, and other nasal structures for any significant morphological changes or lesions. Thus, the animal toxicology studies are used to estimate the risk of inhaled chemicals to human health. The exclusive presentation on anatomy, morphology of olfactory organs and INHAND nomenclature of the histopathological changes would be an interesting lecture to listen in this meeting.

Immuno-oncology is a form of cancer treatment that uses the power of the body's immune system to prevent, control, and eliminate cancer. Rather than killing the tumor-like targeted therapies, immuno-oncology sets out to break tolerance and re-activate the natural defenses by harnessing the power of the immune cells. Cancer immunotherapy has become an appealing and attractive strategy among different therapeutic options over the past years and has shown its ability against malignancies. The immuno-oncology revolution has changed the outcome for patients with various cancers, but there is still work for patients who are not responding to treatments. Most recently, cancer immunotherapy has grown tremendously, such as cancer vaccinations, chimeric antigen receptor (CAR) T-cell therapy, and immune checkpoint blockade therapy. Several clinical trials have investigated their potential in cancer patients' lifesaving. After witnessing the fantastic effect of cancer immunotherapy, it was selected as a topic for this year's STPI conference. I am sure you will be able to learn about this topic from our esteemed panel of speakers.

A few examples of case studies and an interaction with participants, digital pathology and peer review pathology from the experts will be a most sought topics by the participants. I hope the learning from this meeting will be helpful to all participants who want to pursue their careers in toxicologic pathology. I request you advance toxicologic pathology and work towards a healthier future.

I sincerely thank all the Sponsors without whom conducting any event is impossible. I take this opportunity to thank all the speakers who have traveled long distances, sparing their precious time to participate, deliberate, and share their knowledge at this conference.

I profusely thank all the central council members, organizing secretary, organizing committee members, past President's and central council members, and the STP-I members for supporting me and the central council members in organizing this conference. My sincere thanks are also to those directly or indirectly associated with organizing this conference.

With Best Wishes

Venkatesha Udupa  
President, Society of Toxicologic Pathology - India (STP-I)



## PROGRAM OVERVIEW: Friday, 27 October, 2023 (Day 1)



Registration 07.30 am - 08.30 am  
Prayer 08.30 am - 08.35 am  
Welcome Address: Narendra Deshmukh, Vice President 08.35 am - 08.45 am  
Presidential Address: Venkatesha Udupa, President 08.45 am - 08.55 am



Inauguration Address: Pankaj Shah, Chief Guest 08.55 am - 09.15 am  
Vote of Thanks: Praful Patel, General Secretary 09.15 am - 09.20 am  
Homage to Dr. Chirukandath Gopinath 09.20 am - 09.25 am

Chair: S.K. Vijayasarithi, Co-chair: Praful Patel and Sanjay Paneliya



Tracy Carlson 09.30 am - 10.45 am  
**Toxicologic pathology of the ear**



Break 10.45 am - 11.00 am



Ricardo de Miguel and Klaus Weber 11.00 am - 11.45 am  
**Tactile and gustatory sense organs in laboratory animals; anatomy and toxicology**



Christine Frieke Kuper 11.45 am - 12.30 pm  
**Anatomy and morphology of olfactory organ**



Christine Frieke Kuper 12.30 pm - 01.15 pm  
**Histopathology of olfactory structures (INHAND diagnostic) and possible consequences**



Lunch 01.15 pm - 02.00 pm

Chair: Madhav Marathe, Co-chair: Nikita Bhatt and Amod Kale



Jacqueline Brassard 02.00 pm - 02.45 pm  
**Ocular comparative anatomy in preclinical setting**



Meg Ferrell Ramos 02.45 pm - 03.30 pm  
**Ocular physiology and immunology: influences of ocular pathology**



Break 03.30 pm - 03.50 pm


Chair: Narendra Deshmukh, Co-chair: Kalaiselvan Ponnusamy and Sanjay Bokan



Jacqueline Brassard 03.50 pm - 04.35 pm  
**Anterior segment pathology in the context of ocular drug development**



Meg Ferrell Ramos 04.35 pm - 05.15 pm  
**Posterior segment pathology: considerations in ocular drug development**



Cultural event and dinner 07.00 pm - 10.00 pm





## PROGRAM OVERVIEW: Saturday, 28 October, 2023 (Day 2)

Chair: Shekar Chelur, Co-chair: Jomy Jose and Mohmad Sadik Mulla



**Jagadeesh Bayry** 09.00 am - 09.45 am  
**An insight on the basis for immunotherapy in cancer**



**Break** 09.45 am – 10.00 am



**Charu Gupta** 10.00 am – 10.45 am  
**Comparing humanized NSG mouse models to characterize and validate immuno-oncology therapeutics**

Chair: Venkatesha Udupa, Co-chair: Pankaj Shelar and Ashvin Patel



**Dharani K. Ajithdoss** 10.45 am - 11.30 pm  
**Anticancer Innovation: Empowering T Cells**



**Kuno Würsch** 11.30 pm - 12.15 pm  
**ADCs – aspirations for the design of next generation molecules (Online)**



**Florian Colbatzky** 12.15 pm – 1.00 pm  
**SMAC mimetics**



**Lunch and poster evaluation** 01.00 pm - 02.00 pm



**Young scientist poster presentation** 02.00 pm - 02.45 pm

Chair: Kamala Kanan, Co-chair: Shekhar Kadam and Kapil Vinodbhai Vachhani



**Kiran Palyada** 02.45 pm - 03.30 pm  
**IL15-PD1-mediated toxicities in monkeys**



**Break** 03.30 pm - 03.50 pm



**Florian Colbatzky** 03.50 pm - 04.35 pm  
**Immune-mediated adverse effects**



**Award ceremony (young scientist poster, STP-I best poster and IATP Capen award) and group photograph** 04.35 pm - 05.15 pm



**STP-I General body meeting** 05.30 pm - 06.30 pm



**Dinner** 07.30 pm - 10.00 pm



# PROGRAM OVERVIEW

## Sunday, 29 October, 2023 (Day 3)

Chair: Madhusudan, Co-chair: Rajesh Ugalmugle and Madhav Nilakanth Mugale



**Tijo Thomas**

09.00 am - 09.45 am

**Validating a whole slide image management system on a GLP-compliant safety study**



**Klaus Weber**

09.45 am – 10.30 am

**The impact of artefacts on study outcomes; examples of peer reviews, pathology working groups and expert panels**



**Break**

10.30 am – 10.45 am

Chair: Satish Panchal, Co-chair: Krishna Bhagvatulla and Satishkumar Bhalodiya



**Aaron Sargeant**

10.45 am – 11.10 pm

**Case study: Pathologist points to consider when recording findings in carcinogenicity studies, with emphasis on the hematopoietic system**



**Aaron Sargeant**

11.10 am – 11.35 pm

**Case study: The use of error-corrected DNA sequencing to detect carcinogenic processes in Tg.RasH2 mice after three months of exposure to genotoxic and non-genotoxic carcinogens**

Chair: Ramchandra Ranvir, Co-chair: Nataraju and Rajesh K



**Shambhunath Choudhary**

11.35 am – 12.00 pm

**Case study: mRNA vaccines: efficacy and toxicity in preclinical animal models**



**Klaus Weber**

12.00 pm – 12.30 pm

**Case study: Vascular leakage with IL-2 agonists**



**Charu Gupta**

12.30 pm - 01.15 pm

**Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies in Immune Humanized Platforms**



**Venkatesha Udupa**

01.15 pm – 01.30 pm

**Concluding remarks**



**Lunch and departure**

01.30 pm - 02.30 pm

# AWARDS AND POSTERS



## Young Scientist Poster Award

Professor M. K Shingatgeri Memorial Young Scientist Poster Award is instituted by Dr. Vyas M Shingatgeri, Dean at School of Biosciences, Apeejay Stya University, Gurugram, Hariyana, in memory of Late Professor M. K Shingatgeri, Former Dean of Bombay Veterinary College and Professor and Head of its Department of Pharmacology and Toxicology. The award is restricted to the subject of Toxicologic Pathology only. The Poster presentation should be original work and should include title, authors, address, purpose of study, methods, results and conclusions. The name of the presenting author should be underlined.

## STP-I Best Poster Award

The abstract of poster presentation of about 250 words should include title, authors, address, purpose of study, methods, results and conclusions. The name of the presenting author should be underlined.



Abstract with email address should be submitted preferably through E-mail (not as an attachment file but as a body of the mail) to the organizing secretary Dr. Praful Patel (E-mail: [stpi.india@gmail.com](mailto:stpi.india@gmail.com)) latest by 20 October 2023. Poster shall be of size 48 inches (Width) x 36 inches (Height). General template given may be followed.

## IATP Charles Capen Trainee Award

The Charles Capen Trainee Award given by the International Academy of Toxicologic Pathology (IATP) recognizes Dr. Charles Capen and his legacy as a researcher, teacher, and mentor to the pathology and toxicology communities spanning more than four decades. Dr. Capen was recognized worldwide as an exceptional leader in veterinary and biomedical research. He was a highly regarded mentor to numerous graduate students and postdoctoral scientists. His students and trainees are now leaders through out academia, government and industry. The Charles Capen Awards provides classic reference book to the awardee to further his or her training and education in the field of toxicologic pathology.

The successful applicant must be a pathology, toxicology or toxicologic pathology trainee. A trainee is defined as an individual working on an academic degree, in a training or residency program, or in a postdoctoral training position and have demonstrated achievements in the field of toxicologic pathology including but not limited to:

- Research contributing to public safety as it relates to the adverse health effects of xenobiotics;
- Establishing test methods and standards that enhance the field of toxicologic pathology; and/or
- Developing new or novel uses of toxicologic pathology in safety research.

Suggested criteria for the selection of the award recipient will be on poster presentations.

The IATP will present the recipient with an award certificate and 300 USD or equivalent amount in INR. A Fellow of the IATP or an eminent pathologist will present the award certificate and money at the STP-I meeting awards ceremony.

# SPEAKERS



## **Tracy Carlson, DVM, PhD, DACVP**

Dr. Carlson received her DVM at North Carolina State University in 2004 and subsequent PhD in innate immunity/tuberculosis and anatomic pathology residency training at the Ohio State University through 2011. She currently works as a Senior Veterinary Pathologist at Greenfield Pathology Services continuing her career as a medical device and general toxicologic pathologist at Baxter Healthcare Inc, MPI, and Charles River Laboratories. She has been supporting otic histopathology since 2015 providing pathology support and study histopathology evaluations at both MPI and Charles River Laboratories. She is the current chair of the Education Committee for the Society of Toxicologic Pathology and an active member of the Special Interest Groups for the special senses and medical devices. Dr. Carlson has multiple publications including two book chapters on otic pathology currently in progress. She was an invited speaker on pathology of the middle ear for the modular course of the Special Senses for the Society of Toxicologic Pathology in 2019.



## **Ricardo de Miguel, PhD, Dipl. ECVP**

Ricardo graduated as DVM by the University of Zaragoza and lateras MSc (Research) by the University of León. He is PhD in Animal Health and board-certified diplomate of the European College of Veterinary Pathologists (ECVP). He started working for AnaPath Research SAU, an in vivo test facility located in Barcelona (Spain), before moving to AnaPath Services GmbH (Switzerland) to further develop his career as toxicologic pathologist. Experienced investigative pathologist with more than 20 scientific publications and fellowships in the United States, Uruguay, France, and Spain. Deep interest in immunology, immunotoxicology, vaccinology, neuropathology, ocular pathology, special technologies, and medical device.



## **Christine Frieke Kuper, DVM, PhD, DACVP**

Dr. Kuper is a board-certified toxicologic pathologist with extended expertise in respiratory toxicity and immunopathology. She was an invited contributor of workshops at ECVAM and in the US, and a member of working groups like OECD inhalation guidelines, NIEHS, and INHAND harmonization of pathologic nomenclature. Her research on immunopathology and respiratory toxicity included histopathology as well as omics with low-molecular chemical sensitizers. She worked at TNO, the Institution in the Netherlands for Applied Science, and at the RIVM, the Dutch Public Health Institute. She received the BSTP Gopinath Lecture Award in 2016. She is now a private consultant.



# SPEAKERS



## **Jacqueline A. Brassard, DVM, MS, PhD, DACVP**

Dr. Jacqueline Brassard received her D.V.M. degree Texas A&M University (TAMU) in 1979 and practiced companion animal and exotic animal medicine for 3 years. In 1982, she returned to TAMU and completed a combined anatomic and clinical residency in veterinary pathology in 1985 and an M.S. degree in Veterinary Pathology in 1987. She continued her post-DVM pathology education at Washington State University (WSU), where she passed the ACVP certifying exam in 1988 and completed a Ph.D. degree in Veterinary and Comparative Anatomy, Physiology and Pharmacology in 1990. She then joined The Scripps Research Institute (TSRI) in La Jolla, CA as a research associate in molecular hemostasis. In 1996, she began her career as a toxicologic pathologist and worked for Searle, Monsanto, Pharmacia, Pfizer, ICOS, and Allergan pharmaceutical companies before becoming a toxicologic pathology consultant. She has co-authored journal publications and book chapters in hemostasis, ocular drug development, and gene therapy. She has presented on these same topics for the American Society of Hematology, Society of Toxicologic Pathology, and Society of Toxicology. As a member of the Society of Toxicologic Pathology, she served/serves on multiple INHAND Special Senses, including Rodent and Non-rodent Ocular Working Groups and Non-Rodent Ocular Trimming and Sectioning Working Group.



## **Meg Ferrell Ramos, DVM, PhD**

Dr. Ramos received her DVM in 1986 from Washington State University, and immediately moved to Hawaii where she spent six years in small animal practice, followed by six years as a clinical veterinarian at the Honolulu Zoo. She returned to academia taking a fellowship at Johns Hopkins School of Medicine, completing her PhD in Comparative Pathology at University of California, Davis in 2006. Her career path shifted to pharma/biotech, with employment at Allergan and Regeneron, engaged primarily in ocular research and drug development. She is currently employed as a Research Fellow at AbbVie based in Irvine (formerly Allergan) supporting the ocular and large molecule immunology portfolio. Meg has co-authored several manuscripts on ocular drug development and/or pathology including five book chapters, chaired the rodent INHAND Special Senses manuscript, and was guest editor for the STP Toxicologic Pathology ocular edition, published 2021. She currently chairs the committee for INHAND Special Senses, and serves on the IQ Ophthalmic Scoping Group.

# SPEAKERS



## **Prof. Jagadeesh Bayry, BVSc, MVSc, PhD**

Prof. Bayry is a graduate of Veterinary Medicine from Bengaluru (1996) with a specialization of Virology and Immunology from Indian Veterinary Research Institute (1999). He received PhD in Immunology from Sorbonne University, Paris in 2003 and following post-doctoral research at University of Oxford, he joined Institut National de la Santé et de la Recherche Médicale (INSERM, The National Institute of Health and Medical Research), Paris, France in 2006 as a faculty. In 2018, he became Director of Research at INSERM. In 2021, he joined IIT Palakkad as a Professor of Biological Sciences and Engineering. His research is aimed at fundamental Immunology, immunotherapy and host-pathogen interaction. His h-index is 70 and he has authored more than 300 articles with over 17,000 citations. He has received fellowship from the Academy of Translational Medicine Professionals (FACadTM), Austria. Prof. Bayry serves as an Editor, Associate Editor or Editorial Board member of various journals like *Frontiers in Immunology*, *Cellular & Molecular Immunology*, *Immunobiology*, *Discovery Medicine*, *Scientific Reports*, *Immunotherapy*, *Antibodies*, *PLoS ONE*, *Frontiers in Molecular Medicine*, *Virusdisease*, and has edited four books from Springer Publisher. He has also served as a member (2016–2022) of a commission 'LS6-Immunity, Infection and Immunotherapy' at the European Research Council (ERC).



## **Charu Gupta, MTech, PhD**

Dr. Charu Gupta earned her Ph.D. in molecular medicine from the Hannover Medical School, Germany, where she gained mechanistic and therapeutic insights into IDH1-mutated acute myeloblastic leukemia. Her preclinical doctoral and postdoctoral work contributed to the development of several AML pre-clinical models and clinical trials. Her postdoctoral work at the University of Michigan focused on identifying and characterizing adhesion receptors required in neutrophil extravasation to better understand inflammation responses. Along with her research endeavors, Dr. Gupta volunteers as a career podcast host with an online science communication. As a Technical Information Scientist, Charu leverages her experience in mouse disease modeling, immunology, hematology, and oncology to help further global scientific education, rigour and endeavors.

# SPEAKERS



## **Dharani K. Ajithdoss, BVSc, MVSc, PhD, DACVP, DACVM**

**Dr. Dharani K. Ajithdoss currently holds the position of Senior Director of Pathology at Regeneron Pharmaceuticals Inc., New York, USA, where he provides toxicopathological support for the discovery and development of drugs for a variety of human diseases, including Ebola, COVID-19, atopic dermatitis, NASH, and prostate cancer, to name a few. He earned his veterinary medicine degree from Madras Veterinary College, Chennai, India, a graduate degree in microbiology from the College of Veterinary Sciences, Hyderabad, India, and a doctorate degree in molecular virology from Texas A&M University, Texas, USA. He then completed his residency training in anatomic pathology at Texas A&M University. Since 2012, he has been a diplomate of both the American College of Veterinary Pathologists (ACVP) and the American College of Veterinary Microbiologists (ACVM). He had previously been on the faculty at Texas A&M University and Washington State University, where he taught veterinary students, trained pathology, and microbiology residents, provided pathology service, and conducted collaborative research. At Regeneron, he evaluates the safety and efficacy of various therapeutic modalities, including bispecific mAbs, ADCs, AAVs, oncolytic viruses, siRNAs, and CRISPR/Cas9 sgRNAs in a variety of preclinical species. He has broad experience in the pathological evaluation of several established and innovative rodent and nonhuman primate models of human diseases. He has authored or co-authored several peer-reviewed publications in high-impact journals, including Science and Science Translational Medicine, book chapters, regulatory documents, scientific posters, and conference presentations. His leadership role includes directing a pathology team, serving as discovery/digital pathology lead, providing training and mentorship for externs/interns, delivering invited lectures, and serving on various committees of professional societies, such as STP.**

# SPEAKERS



## **Kuno Würsch, DVM, Dipl. ECVP**

**Kuno Würsch is an ECVP board certified pathologist and has received his veterinary diploma from the University of Berne where he also did his doctoral thesis. He has been working as a pathologist and project team member in the pharmaceutical industry for over 15 years and for Novartis for the last 12 years across different modalities. Kuno's focus is Oncology, where he is responsible for safety assessment of innovative medicines such as ADCs, targeted protein degraders, and CAR-Ts. He has a special interest in ADCs and one of his projects has successfully moved to the clinics. He has just recently authored the book chapter on ADCs in the new edition of Current Topics of Nonclinical Drug Development to be published soon.**



## **Florian Colbatzky, DVM, PhD**

**Florian Colbatzky, DVM, PhD, Non-clinical Drug Safety-Germany, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany, started his professional career in academia at the University of Veterinary Medicine in Hanover in 1986. In 1988, he moved to the Institute of Veterinary Pathology, Ludwig-Maximilian-University, Munich, where he stayed until the end of 1993, interrupted by a one-year stay as visiting scientist at the Institute of Pathobiology, Ontario Veterinary College, Guelph, Canada. Since the beginning of 1994, he has worked for BI since 1994 first leading various laboratories (Molecular Pathology, Clinical Pathology, Electron Microscopy), until he became Director Pathology in 2004. In 2019, he was promoted to the position of a Scientific Director providing his expertise within various developmental projects and sharing it with younger colleagues. For many years, he was one of the organizers (and a regular speaker) of the annual seminars "Classical examples of toxicologic pathology" in Hanover.**



# SPEAKERS



## **Kiran Palyada, BVSc, MVSc, PhD, DACVP, DABT**

Kiran Palyada is a diplomate of the American College of Veterinary Pathologists (ACVP) with certification in anatomic pathology. He did his BVSc in Bengaluru, Karnataka and MVSc (pathology) in Hissar, Haryana. After obtaining his PhD in biomedical sciences at Oklahoma State University, Stillwater, OK he pursued his residency in pathology at Cornell University, Ithaca, NY. He has extensive experience working as an anatomic pathologist in both CROs and pharmaceutical industries for over 15 years. He is also a diplomate of the American Board of Toxicology (ABT). He is currently working at Pfizer based in San Diego, California. He is involved in the drug safety evaluation of novel drug candidates (mostly oncology) in both GLP and non-GLP environments. He is a program pathologist for several projects at varying stages of development. He has significant experience in reading carcinogenicity studies and models of animal disease. He has an active interest in male reproductive pathology.



## **Tijo Thomas**

Tijo Thomas heads software development at AIRA MATRIX to deliver pathology image analysis and management solutions. He has led several software projects to completion in a career spanning over 20 years. He has contributed across portfolios such as program management, product development and quality management. A significant portion of his career – over 10 years – Tijo dealt with digital pathology and AI-ML projects.

Tijo's projects are from multiple functional domains such as life sciences, ERP, e-Governance, Document Management Systems and Digital Pathology. A certified Software Quality Analyst (by American Society for Quality), Tijo has been part of many quality initiatives including ISO 9001: 2000 and CMM L5 implementation during his career.

# SPEAKERS



## **Klaus Weber, DVM, PhD, MSBiol, DJSTP**

Klaus Weber was born in East Germany and became a veterinarian and a biologist. He was working in laboratories in East German and also, for several years in human pathology. With over 25 years of professional experience in human and animal pathology. Weber was from 1991–2011 head of pathology at RCC/Harlan Laboratories. Klaus Weber has experience in all laboratory species including fish and invertebrates. His area of work covers short and long term as well as oncogenicity studies with specialties in neuropathology, inhalation pathology, bone marrow differentiation and various other topics. His work resulted in numerous presentations and publications. He founded in 2004 AnaPath GmbH in Switzerland, a holding covering nowadays ten independent pathologists. After termination of his contract with Harlan Laboratories, he founded by the end of 2012 a new company in Switzerland called AnaPath Services GmbH, functionally active from spring 2013 onwards that covers with 32 technicians all subjects on the field of toxicologic pathology including necropsy at client sites and histotechnique including all specialties.



## **Aaron Sargeant, DVM, PhD, DACVP**

Aaron Sargeant completed his DVM and PhD degrees and residency training in veterinary anatomic pathology from The Ohio State University in Columbus, Ohio. He began his career with carcinogenicity studies at Battelle Memorial Institute in Columbus, and for the last 13 years served as study pathologist for many conventional 2-year bioassays in rodents as well as 6-month carcinogenicity studies in the transgenic rasH2 model at Charles River Laboratories (CRL) in Spencerville, Ohio. Most recently, he was a global subject matter expert for carcinogenicity studies at CRL and was the site head of pathology for the Spencerville CRL facility. In 2022, Aaron joined Janssen Pharmaceutical Companies of Johnson & Johnson as Scientific Director, Pathology, where he continues to be involved with various carcinogenicity working groups and programs. Aaron is an active member of the Society of Toxicologic Pathology, where he will finish a term as Secretary-Treasurer in June 2023.

# SPEAKERS



## **Shambhunath Choudhary, DVM, PhD, DACVP, DABT**

**Shambhu is a board-certified toxicologist, veterinary pathologist, and a translational research scientist specialized in cancer biology and vaccine research with organ system expertise in nephrotoxicity, hepatotoxicity, and dermal toxicity. Dr. Choudhary obtained his DVM from Kerala Veterinary College in India, his PhD and postdoctoral research trainings in cancer therapeutics from University of Tennessee, and pathology residency from Kansas State University (KSU). He worked at KSU as a comparative pathologist and at Charles River Laboratories as a toxicologic pathologist before joining Pfizer.**

**At Pfizer, Dr. Choudhary supports drug discovery and development efforts at various research units and serves as a Pathology Therapeutic Area Lead (PTAL) for Vaccine Research Unit in NY. He is active in allied professional societies and has served as chair and/or member on many committees, working groups, and scientific sessions. He has authored over 30 papers in peer-reviewed international journals and is regularly invited to speak at international/national meetings and university seminars. He serves as an editorial board member/reviewer for many international journals and as a panelist for many fellowships, grants, and awards.**

# OUR SPONSORS



## DIAMOND



## Platinum



## Gold



## Conference






# About Ahmedabad



The earliest settlements of the city were situated south of the current old city and on the bank of Sabarmati river. It was known as Ashaval or Ashapalli. In the 11th century, Karna of the Chaulukya dynasty made the town his capital and named it Karnavati (Karna's town). It was inscribed as the World Heritage City by UNESCO in July 2017. The old city features rich wooden architecture, havelis, khadkis, and pols. The wooden architecture is exemplary of the unique heritage and culture in Ahmedabad. It signifies contributions to arts and crafts, traditions, and structure design, and is reflective of the city's occupants. The city's architecture was designed to promote a sense of community, family, and multiculturalism. This is evident in the city being home to institutions belonging to several religions including Hinduism, Islam, Christianity, and Judaism.

Ahmedabad has emerged as an important economic and industrial hub in India. It is the second-largest producer of cotton in India, due to which it was known as the 'Manchester of India' along with Kanpur. Cricket is a popular sport in Ahmedabad; a newly built stadium, called Narendra Modi Stadium at Motera can accommodate 132,000 spectators, making it the largest stadium in the world. Ahmedabad observes a range of festivals.



Celebrations and observances include Uttarayan, an annual kite-flying day on 14th and 15th January. Nine nights of Navratri are celebrated with people performing Garba, the most popular folk dance of Gujarat, at venues across the city. The annual Rath Yatra procession on the Ashadh-sud-bij date of the Hindu calendar at the Jagannath Temple. Festivals like Diwali, Holi, Christmas and Muharram (pan India festivals) are also celebrated

# Get ready to explore !



## Akshardham Temple Gandhinagar

The term Akshardham means the divine abode of God and as the name specifies, Akshardham temple of Gandhinagar was built in honour of Swaminarayan by BAPS Swaminarayan Sanstha. The best place to visit that have its Pradarshini and first laser show.

## Adalaj Step tell

The Adalaj stepwell or 'Vav', as it is called in Gujarati, is intricately carved and is five stories deep. It was built in 1498. An inscription in Sanskrit establishes the history of the Adalaj stepwell found on a marble slab positioned in a recess on the first floor, from the eastern entry to the well.



## Modhera sun temple

As one traverses the length and breadth of Gujarat, one constantly stumbles across architectural legacies of the 'Solanki' rule. You keep coming across living spaces and monuments of another time, offering an eclectic glimpse of the artistic and ingenious beauty that makes this exotically state vibrant. A soothing drive amidst green farmlands almost 25 km away from Mehsana on the way to the temples of goddess Bahucharaji reposes the village of Modhera. Set along the backdrop of River Pushpavati, surrounded by a terra-formed garden of flowering trees and songs of birds, rests the famed Sun temple of Modhera.



## Lothal

About 80km southwest of Ahmedabad, the city that stood at this archaeological site 4500 years ago was one of the most important of the Indus Valley civilisation, which extended into what is now Pakistan. Excavations have revealed the world's oldest known artificial dock, which was connected to an old course of the Sabarmati River. Other features include the acropolis, the lower town, the bead factory, the warehouses, and the drainage system. The site has been nominated to be enlisted as a UNESCO World Heritage Site.



## Statue of Unity

The 182-metre (600 feet aprox.) tall statue has been built as an ode to the Iron Man of India, Sardar Vallabhbhai Patel, the first home minister of independent India. The colossal monument towers over River Narmada. The Statue of Unity overlooks the vast surrounds and the river basin of the Narmada River and the sprawling Sardar Sarovar dam. It stands on the Sadhu Bet hillock, connected by a 300-metre bridge, which offers access from the mainland to the statue.

AND MANY MORE!!

**Contact for Tours and Travel Assistance**

Akshar Tours & Travels: Harshil Barot, WhatsApp No. +91 98251 16560, email-[domestic1@akshartours.com](mailto:domestic1@akshartours.com)

Travel and Ease: Himanshu WhatsApp No. +91 98240 08686, email- [Himanshu@TravelnEase.com](mailto:Himanshu@TravelnEase.com)





# NARAYANI HEIGHTS

Email ID: [info@narayaniheights.com](mailto:info@narayaniheights.com)

Phone No: +91 79 6170 1800



## Hotels near by

**Hotel Galaxy Inn**

1.3 Km

**Hotel German Palace**

1.6 Km

**Apricot Hotel**

4.2 Km

**Tribeca Select**

1.6 Km

**Hotel Kanan**

1.9 Km

**Pristine Presidency**

4.9 Km


**The Ummed Ahmedabad**

4.5 Km

# STP-I Executive Committee




Venkatesha Udupa  
MVSc, MSc (Tox), PhD,  
ERT, DABT, DSP  
President



Narendra Deshmukh  
MVSc, DABT  
Vice President



Prafulkumar Patel  
MVSc, PhD, DIBTP  
General Secretary



Satish Panchal  
MVSc, DIBTP, DABT, ERT  
Treasurer



Sanjaykumar Paneliya  
MVSc, PhD, DIBTP  
Member



Nikita Bhatt  
MVSc, DIBTP  
Member



Mahesh Brahmankar  
MVSc, DIBTP, DICVP  
Member



# Conference Organizing Committee



**Venkatesha Udupa**  
MVSc, MSc (Tox), PhD,  
ERT, DABT, DSP



**Narendra Deshmukh**  
MVSc, DABT



**Prafulkumar Patel**  
MVSc, PhD, DIBTP



**Satish Panchal**  
MVSc, DIBTP, DABT, ERT



**Kamala Kannan**  
MVSc, DIBTP



**Sanjaykumar Paneliya**  
MVSc, PhD, DIBTP



**Nikita Bhatt**  
MVSc, DIBTP



**Mahesh Brahmankar**  
MVSc, DIBTP, DICVP



**Ashvin K Patel**  
MVSc, DIBTP



**Bipin Trada**  
MVSc



**Shekhar B. Kadam**  
MVSc, DIBTP, DABT



**Satishkumar Bhalodiya**  
MVSc, DIBTP, ERT, DABT



**Vishal Patel**  
MVSc



**Urvit Patel**  
MVSc



**Pratik Panchal**  
MVSc



**Kaushik Thakor**  
MVSc, PhD



# Society of Toxicologic Pathology - India (STP-I)

**#29, 1st cross, Malleshwaram, Bangalore - 560 003, Karnataka, India**

**Email: [stpi.india@gmail.com](mailto:stpi.india@gmail.com)**

**[www.toxpathindia.com](http://www.toxpathindia.com)**

